Insight Molecular Diagnostics Inc. (IMDX) vs Unicycive Therapeutics, Inc. (UNCY)
A side-by-side comparison of Insight Molecular Diagnostics Inc. and Unicycive Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMDX
Insight Molecular Diagnostics Inc.
$3.38HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
UNCY
Unicycive Therapeutics, Inc.
$4.23HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — IMDX vs UNCY
growth of $100 · dividends reinvested · last 5yIMDX -96.7% (-49.4%/yr)UNCY -91.6% (-39.1%/yr)UNCY compounded faster over this window
IMDX UNCY
IMDX vs UNCY: by the numbers
- •UNCY is the larger company ($113M vs $109M market cap).
- •Both run net losses; UNCY's is the smaller (0.00% vs -2955.63% net margin).
Metrics side by side
Valuation
| Metric | IMDX | UNCY |
|---|---|---|
| P/S ratio | 65.35 | N/A |
| P/B ratio | N/A | 2.12 |
Profitability
| Metric | IMDX | UNCY |
|---|---|---|
| Gross margin | 11.17% | 0.00% |
| Operating margin | -754.08% | 0.00% |
| Net margin | -2955.63% | 0.00% |
| ROE | N/A | -66.12% |
| ROIC | -223.06% | -62.15% |
Growth (annualized)
| Metric | IMDX | UNCY |
|---|---|---|
| Revenue CAGR (5Y) | 27.24% | N/A |
| Total return CAGR (5Y) | -44.39% | -32.14% |
Frequently asked
- How have IMDX and UNCY total returns compared?
- Over the past 5 years, IMDX delivered -44.39% and UNCY delivered -32.14% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Insight Molecular Diagnostics ROEUnicycive Therapeutics ROEInsight Molecular Diagnostics operating marginUnicycive Therapeutics operating marginInsight Molecular Diagnostics revenue growthUnicycive Therapeutics revenue growthInsight Molecular Diagnostics free cash flowUnicycive Therapeutics free cash flow
Insight Molecular Diagnostics & Unicycive Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.